On March 24^th, 2025, Zonhonbio's independently developed Class I new biologic drug—ZHB117 sublingual tablets, which holds full intellectual property rights both domestically and internationally—received the "Drug Clinical Trial Approval Notice" from China's National Medical Products Administration (NMPA). The approved indication for ZHB117 is desensitization therapy for adult allergic rhinitis or rhinoconjunctivitis (with or without allergic asthma) caused by cat allergen sensitivity.